胰腺癌切缘近或阳性术后辅助立体定向体部放疗的前瞻性研究初步结果
这项前瞻性观察研究纳入50例(49例可分析)病理证实的T1-4N0-1M0胰腺腺癌伴切缘阳性(≤1 mm)或近切缘(<2.5 mm)患者,术后接受36 Gy分3次照射切缘部位。中位总生存23.7个月,1年局部无进展生存85%,≥3级放疗毒性仅4.1%(2例)。作者认为辅助胰腺SBRT安全可行,局部和区域控制良好。
要点
- 近或阳性切缘胰腺癌术后行36 Gy分3次SBRT,中位总生存23.7个月(95%CI 13.6-33.8)。
- 1年和2年局部无进展生存分别为85%和77%,区域无进展生存均为73%。
- ≥3级放疗毒性发生率为4.1%(2例),SBRT仅1周不影响全身多药化疗。
核心结论
- 辅助胰腺SBRT对高危胰腺腺癌伴近或阳性切缘患者是安全可行的治疗选择。
- 作者报告该治疗获得显著的局部和区域控制且急性毒性发生率低,SBRT仅1周可安全穿插于全身多药化疗周期之间而不中断给药。
- 这是首项针对高危术后胰腺癌SBRT的前瞻性研究。
研究设计与样本
- 前瞻性观察研究,纳入病理证实的T1-4N0-1M0胰腺腺癌伴切缘阳性(≤1 mm)或近切缘(<2.5 mm)患者。
- 2013年2月至2018年1月共入组50例,49例按方案治疗并纳入分析;中位年龄71岁。
- 符合全身治疗条件者接受新辅助或辅助化疗;所有患者对近或阳性切缘部位接受36 Gy分3次照射。
主要发现
- 中位临床靶区体积11.3 cc,中位计划靶区体积22.0 cc。
- 中位总生存23.7个月(95%CI 13.6-33.8)。
- 1年和2年局部无进展生存分别为85%和77%。
- 1年和2年区域无进展生存均为73%;1年和2年远处无转移生存分别为57%和49%。
- ≥3级放疗毒性发生率为4.1%,发生于2例患者。
临床怎么用
- 作者认为辅助胰腺SBRT是近或阳性切缘高危胰腺腺癌患者安全可行的治疗选择。
- 作者报告SBRT仅1周治疗,可安全穿插于全身多药化疗周期之间而不中断化疗给药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with close or positive margins after surgery for pancreatic carcinoma are at a high risk for recurrence. Stereotactic body radiation therapy (SBRT) allows for safe dose escalation with great conformity and short duration of treatment. Herein, we report the initial results of a prospective observational study that evaluated the efficacy and safety of this treatment option. METHODS AND MATERIALS: Patients eligible for the study had pathologically proven T1-4N0-1M0 pancreatic adenocarcinoma with a positive margin (≤1 mm) or a close margin defined as <2.5 mm. Patients were treated with either neoadjuvant or adjuvant chemotherapy, if eligible for systemic therapy. All patients received 36 Gy in 3 fractions to the close or positive margin site. RESULTS: From February 2013 to January 2018, 50 patients were enrolled with 49 patients treated on protocol and included in the analysis. The median age was 71 years. The median clinical target volume was 11.3 cc and median planning target volume 22.0 cc. The median overall survival was 23.7 months (95% confidence interval, 13.6-33.8). Local progression-free survival at 1 and 2 years was 85% and 77%, respectively. Regional progression-free survival at 1 and 2 years was 73% and 73%, respectively. Distant metastases-free survival was 57% and 49% at 1 and 2 years, respectively. Grade 3+ radiation toxicity was only 4.1% and occurred in 2 patients. CONCLUSIONS: Adjuvant pancreatic SBRT was shown to be a safe and feasible treatment option for patients with high-risk pancreatic adenocarcinoma and close or positive margins. This is the first prospective study of SBRT in high-risk postoperative pancreatic cancer. Our results yielded significant local and regional control with low rates of acute toxicity. This technique does not interrupt the administration of systemically dosed multiagent chemotherapy and can be safely interdigitated between cycles because SBRT is only 1 week of treatment.
引用
- Bernard ME, Sutera PA, Iarrobino NA, et al. Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins. Adv Radiat Oncol. 2018. PMID: 31011674. doi:10.1016/j.adro.2018.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。